Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.48 |
| ▸ | GLS | O94925 | 3/20 | 0.44 |
| ▸ | NAMPT | P43490 | 2/20 | 0.43 |
| ▸ | CCKBR | P32239 | 1/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.41 |
| ▸ | KDM4A | O75164 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.40 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18630525 | 0.84 | BRD4 (0.53) | BRD4GLSNAMPTCCKBRCREBBP | |
| SCHEMBL22989302 | 0.81 | BRD4 (0.47) | BRD4GLSNAMPTCCKBRCREBBP | |
| SCHEMBL31709823 | 0.81 | BRD4 (0.54) | BRD4GLSNAMPTCCKBRCREBBP | |
| SCHEMBL731764 | 0.81 | BRD4 (0.54) | BRD4GLSNAMPTCCKBRCREBBP | |
| SCHEMBL4751779 | 0.81 | AURKB (0.49) | BRD4GLSNAMPTCCKBRAURKA | |
| SCHEMBL7564751 | 0.79 | BRD4 (0.47) | BRD4GLSNAMPTCCKBRCREBBP | |
| SCHEMBL3507808 | 0.79 | BRD4 (0.53) | BRD4GLSNAMPTCCKBRAURKA | |
| SCHEMBL29289884 | 0.79 | BRD4 (0.53) | BRD4GLSNAMPTCCKBRCREBBP | |
| SCHEMBL1111369 | 0.78 | GLS (0.52) | BRD4GLSNAMPTCREBBPKDM4A | |
| SCHEMBL30151702 | 0.78 | GLS (0.52) | BRD4GLSNAMPTCREBBPKDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6465656-B2 | ACYLATING/ACETYLATING ARYLHYDRAZINE, REACTING HYDROZONOYL HALIDE/SULFATE WITH AMINE BASE TO FORM 1-(3-CYANO)PHENYL-2-(TRIFLUOROACETYL)HYDRAZINE | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-10-15 | — | — | US | disclosed |
| EP-1222172-A1 | SYNTHESIS OF 1,3,5-TRISUBSTITUTED PYRAZOLES AND INTERMEDIATES THEREFORE | Bristol-Myers Squibb Pharma Company (US) | 2002-07-17 | — | — | EP | disclosed |
| US-20020055641-A1 | Synthesis of 1,3,5-trisubstituted pyrazoles | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-05-09 | — | — | US | disclosed |
| US-6329527-B1 | ACYLATING SUBSTITUTEDARYL HYDRAZINE, FORMING DIPOLAR COMPOUND, CONTACTING DIPOLAROPHILE AND SUBJECTING TO OXIDATION, REMOVING PROTECTING GROUP | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2001-12-11 | — | — | US | disclosed |
| WO-2001029006-A1 | SYNTHESIS OF 1,3,5-TRISUBSTITUTED PYRAZOLES AND INTERMEDIATES THEREFORE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055641-A1 | Synthesis of 1,3,5-trisubstituted pyrazoles | TFPI, SERPINC1, F11 | BRD4 1251/4885GLS 1412/4885NAMPT 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.